Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
LPCN > SEC Filings for LPCN > Form 8-K on 3-Sep-2013All Recent SEC Filings

Show all filings for LIPOCINE INC.

Form 8-K for LIPOCINE INC.


3-Sep-2013

Entry into a Material Definitive Agreement


ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On August 27, 2013, Lipocine Inc. entered into an Agreement for the Manufacture of Testosterone Undecanoate Liquid Fill Capsules and the Conduct of an ICH Stability Study in Support of Product Registration with Encap Drug Delivery, or Encap, a United Kingdom based contract manufacturer, pursuant to which Encap will manufacture and supply to Lipocine a total of six lots of LPCN 1021 capsules under current good manufacturing practices, using active pharmaceutical ingredients supplied by Lipocine. Encap will manufacture two strengths of the product, three lots of each strength. These lots will be used in Lipocine's planned Phase III study for LPCN 1021. Under the agreement, Encap will also conduct an International Conference on Harmonisation stability program on all six capsule lots in support of Lipocine's planned new drug application filing for LPCN 1021.

Lipocine may terminate the agreement prior to the commencement of any project work stage (as defined in the agreement) without penalty. Lipocine may also terminate the agreement after authorizing commencement of a stage or after confirmation of a purchase order, subject to payment of cancellation fees. Lipocine and Encap may each terminate the agreement upon a material breach of the agreement by the other party, so long as the other party has not cured such breach within a defined period after written notice of the breach by the non-breaching party. Lipocine also has the right to terminate the agreement for other good cause, including technical, scientific or business reasons, upon a minimum period of written notice to Encap. If Encap achieves certain milestones by the applicable due dates, Lipocine will be obligated to purchase a percent of its commercial supply of LPCN 1021 from Encap for a limited time period, subject to Lipocine's right to buy out such commitment on terms to be negotiated.

The foregoing does not purport to be a complete description of the agreement, and is qualified by reference to the full text of such document, which Lipocine will file in a subsequent filing with the Securities and Exchange Commission.


  Add LPCN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for LPCN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.